Prognostic significance of hemorrhage requiring embolization in the setting of previously treated head and neck squamous cell carcinoma: Systematic review and retrospective cohort

Abstract Background The management of acute hemorrhage in patients with previously treated head and neck squamous cell carcinoma (HNSCC) is challenging due to the lack of substantial evidence to guide clinical decision making. Methods A systematic review and retrospective chart review were performed...

Full description

Saved in:
Bibliographic Details
Published in:Head & neck 2024-07
Main Authors: Karadaghy, Omar A., Peterson, Andrew M., Sawaf, Tuleen, Renslo, Bryan, Miller, Brevin, Virgen, Celina, Sykes, Kevin J., Doering, Michelle M., Moran, Christopher J., Ullman, Henrik, Peterson, Jeremy, Pipkorn, Patrik, Bur, Andrés M.
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background The management of acute hemorrhage in patients with previously treated head and neck squamous cell carcinoma (HNSCC) is challenging due to the lack of substantial evidence to guide clinical decision making. Methods A systematic review and retrospective chart review were performed to identify patients with a history of HNSCC who underwent either primary or adjuvant radiation therapy (RT) and presented with hemorrhagic complications requiring embolization. Patient characteristics, history, presentation, and outcomes were reviewed. Results The systematic review included a total of 182 patients. Heterogeneity existed in outcomes reporting; 1‐year overall survival approached 50%. From the retrospective chart review, 51 patients were included. Median survival time following hemorrhage was 2.2 months (range 1.2–11.4 months). Patients with malignancy at time of hemorrhage were identified as having worse survival. Conclusions Acute hemorrhage in patients with a history of previously radiated HNSCC portends a high risk of mortality, with patients with active malignancy representing a worse prognostic group.
ISSN:1043-3074
1097-0347
1097-0347
DOI:10.1002/hed.27875